Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Association of MBL and ficolin-2 with SSc disease manifestations

From: Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study

Variables MBL levels (μg/ml), median (IQR) MBL2low-producing genotype, n (%) Ficolin-2 levels (μg/ml), mean (SD)
Skin manifestations    
Calcinosis (yes vs. no) 2.1 (0.7-3.2) vs. 0.8 (0.1-2.1) 2 (7) vs. 16 (27) 0.6 (0.3) vs. 0.6 (0.3)
  P value 0.005 0.02 0.9
Pitting (yes vs. no) 1.8 (0.5-3.0) vs. 0.8 (0.1-1.9) 6 (13) vs. 12 (29) 0.6 (0.4) vs. 0.5 (0.3)
  P value 0.007 0.06 0.2
Digital ulcers (yes vs. no) 2.7 (1.0-4.1) vs. 1.0 (0.2-2.3) 1 (8) vs. 17 (22) 0.6 (0.4) vs. 0.6 (0.3)
  P value 0.01 0.2 0.5
Organ involvement    
PAH (yes vs. no) 1.7 (0.3-3.8) vs. 1.1 (0.3-2.6) 1 (13) vs. 17 (21) 0.5 (0.2) vs. 0.6 (0.4)
  P value 0.5 1 0.6
ILD (yes vs. no) 1.7 (0.5-2.9) vs. 0.9 (0.2-2.1) 6 (15) vs. 12 (25) 0.7 (0.3) vs. 0.5 (0.3)
  P value 0.11 0.3 0.04
Renal crisis (yes vs. no) 1.7 (0.2-4.1) vs. 1.1 (0.3-2.6) 1 (25) vs. 17 (20) 1.0 (0.3) vs. 0.6 (0.3)
  P value 0.6 1 0.01
Bowel dysmotility (yes vs. no) 3.1 (0.8-4.2) vs. 1.1 (0.3-2.4) 1 (11) vs. 17 (21) 0.6 (0.3) vs. 0.4 (0.2)
  P value 0.14 0.7 0.04
  1. ILD, interstitial lung disease; IQR, interquartile range; MBL, mannose-binding lectin; PAH, pulmonary arterial hypertension; SD, standard deviation; SSc, systemic sclerosis.